Treatment with Phosphodiesterase Inhibitors Type III and V: Milrinone and Sildenafil is an Effective Combination During Thromboxane-induced Acute Pulmonary Hypertension
Overview
Affiliations
Objectives: To evaluate the effects of phosphodiesterase type III and V (PDEIII and PDEV) inhibition on pulmonary and systemic haemodynamics in a porcine model of acute pulmonary hypertension.
Methods: Twenty-four adult swine were anaesthetized with 1 MAC isoflurane and mechanically ventilated with an FI(O(2)) of 100%. Micromanometer-tipped catheters were placed in the ascending aorta, pulmonary artery and right ventricle. Pulmonary flow was measured with a perivascular probe using transit time ultrasound. Pulmonary hypertension was induced with a continuous infusion of the thromboxane analogue, U46619. The animals were then randomized to four groups: Group 1 (n=6) received 50 mg of sildenafil (PDEV inhibitor) diluted in water via an orogastric tube; Group 2 (n=6) received 50 microg kg(-1) of i.v. milrinone (PDEIII inhibitor); Group 3 (n=6) received sildenafil followed by milrinone; and Group 4 (n=6) received placebo via an orogastric tube.
Results: Pulmonary hypertension was achieved in all animals. Calculated pulmonary vascular resistance decreased by an average of 36% after sildenafil (P<0.05), 41% after milrinone (P<0.05), and 61% with both drugs combined (P<0.05). Systemic vascular resistance decreased by 37% (P<0.05) with milrinone alone, and 36% (P<0.05) with milrinone and sildenafil combined but it was preserved in the sildenafil group. Cardiac output and right ventricular dP/dT were significantly improved after milrinone or both drugs combined, but not with sildenafil.
Conclusion: Milrinone and sildenafil are effective pulmonary vasodilators, with independent action and additive effect. Both drugs combined achieved a better haemodynamic profile, with greater pulmonary vasodilatation and increased contractility but without additional systemic vasodilatation. The systemic haemodynamic profile (systemic vasodilation, cardiac output, right ventricular dP/dT) is improved with milrinone but not with sildenafil.
Perioperative Management of Pulmonary Hypertension. a Review.
Wood C, Balciunas M, Lordan J, Mellor A J Crit Care Med (Targu Mures). 2021; 7(2):83-96.
PMID: 34722909 PMC: 8519362. DOI: 10.2478/jccm-2021-0007.
Levosimendan, milrinone, and dobutamine in experimental acute pulmonary embolism.
Lyhne M, Dragsbaek S, Hansen J, Schultz J, Andersen A, Nielsen-Kudsk J Pulm Circ. 2021; 11(3):20458940211022977.
PMID: 34178307 PMC: 8207288. DOI: 10.1177/20458940211022977.
El-Ghandour M, Hammad B, Ghanem M, Antonios M Paediatr Drugs. 2020; 22(6):685-693.
PMID: 32856285 PMC: 7453074. DOI: 10.1007/s40272-020-00412-4.
Nakata T, Tanaka R, Yoshiyuki R, Fukayama T, Goya S, Fukushima R J Cardiovasc Pharmacol. 2015; 65(6):640-8.
PMID: 25806612 PMC: 4461396. DOI: 10.1097/FJC.0000000000000236.
Farah P, Ahmad-Ali A, Hanane G, Abbas E Iran J Pediatr. 2013; 23(1):19-26.
PMID: 23550065 PMC: 3574987.